Published in Rev Urol on January 01, 2006
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Recent trends in antibody-based oncologic imaging. Cancer Lett (2011) 1.17
Antibody-based imaging of HER-2: moving into the clinic. Curr Mol Med (2013) 0.76
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol (2003) 3.58
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 2.77
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res (2003) 2.11
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res (1988) 1.91
Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol (2004) 1.85
Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol (2003) 1.74
Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology (1994) 1.64
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med (2003) 1.61
Current status of local salvage therapies following radiation failure for prostate cancer. J Urol (2005) 1.57
Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate (1997) 1.25
Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology (2003) 1.23
111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol (1998) 1.16
Spread of prostate carcinoma to the perirectal lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma. Am J Surg Pathol (2004) 1.14
Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol (2004) 1.08
Two different lymph node metastatic patterns of a prostatic cancer. Cancer (1990) 1.00
Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology (1999) 0.97
Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer (2005) 0.96
Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol (1998) 0.94
Positron emission tomography for urological tumours. BJU Int (2003) 0.93
The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol (2004) 0.93
Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate (1997) 0.91
Positron emission tomography in urologic oncology. Cancer Control (2002) 0.90
Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer (1998) 0.90
Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys (2001) 0.87
The accuracy of CT in the staging of carcinoma of the prostate. AJR Am J Roentgenol (1987) 0.86
Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med (2004) 0.85
Imaging clinically localized prostate cancer. Urol Clin North Am (2003) 0.85
Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate (1994) 0.80
Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Int J Radiat Oncol Biol Phys (2003) 0.80
CAT scanning in staging of prostatic cancer. Urology (1981) 0.80
Pelvic adenopathy from bladder and prostate carcinoma: detection by rapid-sequence computed tomography. AJR Am J Roentgenol (1983) 0.79
Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer. Scand J Urol Nephrol (1998) 0.78
ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol (2005) 0.78
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol (2003) 4.28
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol (2003) 2.40
Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res (2007) 2.34
Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol (2003) 2.10
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol (2003) 2.06
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol (2004) 1.91
PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol (2008) 1.91
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol (2007) 1.71
ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther (2011) 1.56
Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene (2002) 1.55
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
Chronic calcific pancreatitis: combination ERCP and extracorporeal shock wave lithotripsy for pancreatic duct stones. South Med J (2010) 1.52
Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc (2006) 1.50
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol (2008) 1.46
Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. BJU Int (2008) 1.43
Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology (2010) 1.43
Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res (2008) 1.35
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther (2007) 1.27
PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res (2003) 1.25
Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care (2010) 1.24
Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res (2006) 1.22
The burden of prostate cancer in Asian nations. J Carcinog (2012) 1.19
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther (2008) 1.19
Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol (2012) 1.17
Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther (2006) 1.16
Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology (2012) 1.16
Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol (2007) 1.12
Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol (2010) 1.12
A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem (2008) 1.11
Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res (2010) 1.09
Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab (2012) 1.08
Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci (2008) 1.07
The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate (2009) 1.06
The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int (2006) 1.04
Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci (2013) 1.03
Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin. Int J Oncol (2007) 1.03
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep (2002) 1.02
Prostate cancer in men less than the age of 50: a comparison of race and outcomes. Urology (2011) 1.02
Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int (2011) 0.98
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology (2009) 0.97
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology (2006) 0.97
Partial segmental thrombosis of corpus cavernosum: case report and review of world literature. Urology (2005) 0.97
Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess. Urology (2004) 0.96
Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort. Prostate Cancer (2011) 0.96
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest (2013) 0.96
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res (2005) 0.94
Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev (2010) 0.93
Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int (2005) 0.93
Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology (2008) 0.93
Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles. Int J Oncol (2007) 0.93
Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer (2008) 0.92
Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. J Urol (2010) 0.91
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets (2009) 0.91
Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells. Exp Cell Res (2007) 0.91
Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med (2011) 0.88
Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res (2008) 0.87
Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol (2008) 0.87
Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis. J Zhejiang Univ Sci B (2007) 0.87
Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. J Urol (2005) 0.87
The multi-disciplinary management of high-risk prostate cancer. Urol Oncol (2009) 0.86
Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol (2004) 0.86
Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India. J Cancer (2013) 0.85
Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. Int J Radiat Oncol Biol Phys (2003) 0.85
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. Urology (2011) 0.85
Clinicopathological behavior of single focus prostate adenocarcinoma. J Urol (2009) 0.85
Merkel cell carcinoma as a solitary metastasis to the testis. J Clin Oncol (2007) 0.84
Lymphovascular invasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomy. Cancer (2006) 0.84
Inferior vena cava reconstruction using fresh inferior vena cava allograft following caval resection for leiomyosarcoma: midterm results. J Vasc Surg (2007) 0.84
Evaluation of ERG responsive proteome in prostate cancer. Prostate (2013) 0.83
Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat. Urol Oncol (2011) 0.83
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol (2005) 0.83
Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer. Curr Opin Urol (2005) 0.83
Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology (2007) 0.83
The design and implementation of a multidisciplinary prostate cancer clinic. Urol Nurs (2007) 0.83
The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol (2005) 0.83
The effective management of biochemical recurrence in patients with prostate cancer. Rev Urol (2005) 0.83
Managing prostate cancer: the role of hormone therapy. Can J Urol (2007) 0.82
Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review. Urology (2007) 0.82
Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. Clin Cancer Res (2003) 0.82
Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft. Urol Oncol (2003) 0.81
ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity. Monoclon Antib Immunodiagn Immunother (2014) 0.81
Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. Int J Gen Med (2011) 0.81
Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients. Int J Cancer (2011) 0.80
Concomitant intraoperative renal artery embolization and resection of complex renal carcinoma. J Vasc Surg (2003) 0.80
Health-related quality of life for men with prostate cancer--an evaluation of outcomes 12-24 months after treatment. Urol Oncol (2012) 0.80